EFPIA Newsletter 05 October 2023

EFPIA's response to the European Commission's proposals to revise the pharmaceutical legislation     Back innovation in the EU pharma legislation   Let’s not slow down medical innovation in Europe: the EU pharmaceutical legislation will shape the future of research, development and manufacturing in Europe for decades to come. Unless changes are made, Europe will become reliant on other regions' medical innovation and our citizens will wait longer for the latest advances in care. How can the pharma legislation help close the gap? Read EFPIA's proposals.   Read more →

World Heart Day Do you know that 1 in 2 heart attacks are repeat episodes? It’s time to get to the heart of the issue and improve the lives of the 60 million people living with cardio-vascular diseases in the EU. Read more in this blog by the EFPIA CVD Platform.

Blogs     05 October 2023 Supporting Europe’s Informal Carers: a call to action for Pharma companies Informal carers across the EU play an invaluable role in the healthcare ecosystem. They provide essential physical,... Read more →         04 October 2023 Precision Medicine and Population Health: a contradiction or a way forward? By focusing on individual information and genomics and channeling the right approach to the right patient at the right... Read more →

Are medicines affordable for health systems?

Despite representing 15% of health spending on average across Europe for the past 20 years, pharmaceutical expenditure has long been a focal point of health authorities and political debates. A broader understanding is needed about the role of investment in therapeutic innovation to deliver improved health outcomes, cost offsets for health systems, and to generate productive economies. Watch the recording of the EFPIA event at Gastein 2023 to discuss whether medicines are affordable for health systems.

Events     10 OCT 2023   Supporting the Global Response to Antimicrobial Resistance Through Innovation De Warande, Brussels Join us and explore innovative policy instruments and initiatives driving AMR treatment and access to novel antimicrobials.... Learn more →       12 OCT 2023   PMNET Forum - an international precision medicine networking forum National Library of Latvia in Riga The world's leading experts will meet in Riga to promote precision medicine Learn more →

	17 OCT 2023			EFGCP Better Medicines for Children Conference 2023 Amsterdam Global Paediatric Drug Development: the value of multi-stakeholders’ collaboration Learn more →

	24 OCT 2023			POLITICO Health Care Summit Brussels and online From pandemic to permacrisis? Europe’s next health care challenge Learn more →

How the proposed EU pharma legislation would impact rare disease patients? As currently written, the proposals would have a negative impact on the development of 45 products in Europe corresponding to a 12% decrease in innovation. This could deprive around 1.5 million European rare disease patients of a novel treatment option and would mean a further decrease by €4.5 billion in R&D spending in Europe. Read more in our new report.

What we are reading Aviva backs £1bn cancer hub in London 02 October 2023  (pharmaphorum) Read more →

About the EFPIA newsletter The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55 Communications@efpia.eu ▶ in

EFPIA 2026 All rights reserved  ·  Disclaimer  ·  Unsubscribe